Aristotle Atlantic Partners LLC Sells 9,323 Shares of Abbott Laboratories $ABT

Aristotle Atlantic Partners LLC trimmed its position in Abbott Laboratories (NYSE:ABT) by 48.9% during the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 9,727 shares of the healthcare product maker’s stock after selling 9,323 shares during the quarter. Aristotle Atlantic Partners LLC’s holdings in Abbott Laboratories were worth $999,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Waverly Advisors LLC increased its position in Abbott Laboratories by 16.3% during the first quarter. Waverly Advisors LLC now owns 128,054 shares of the healthcare product maker’s stock worth $13,147,000 after acquiring an additional 17,977 shares during the period. Dempze Nancy E grew its position in shares of Abbott Laboratories by 2.6% during the 1st quarter. Dempze Nancy E now owns 44,350 shares of the healthcare product maker’s stock worth $4,553,000 after purchasing an additional 1,115 shares in the last quarter. Entropy Technologies LP grew its position in shares of Abbott Laboratories by 45.9% during the 1st quarter. Entropy Technologies LP now owns 172,145 shares of the healthcare product maker’s stock worth $17,674,000 after purchasing an additional 54,121 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund increased its holdings in shares of Abbott Laboratories by 11.5% during the first quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 975,819 shares of the healthcare product maker’s stock worth $100,187,000 after purchasing an additional 100,479 shares during the period. Finally, Renaissance Technologies LLC raised its position in shares of Abbott Laboratories by 122.0% in the first quarter. Renaissance Technologies LLC now owns 1,238,666 shares of the healthcare product maker’s stock valued at $127,174,000 after buying an additional 680,600 shares in the last quarter. Institutional investors own 75.18% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on ABT shares. Oppenheimer lowered their price objective on Abbott Laboratories from $132.00 to $115.00 and set an “outperform” rating on the stock in a research note on Friday, April 17th. Sanford C. Bernstein cut their target price on Abbott Laboratories from $125.00 to $110.00 and set an “outperform” rating for the company in a research report on Friday, April 17th. The Goldman Sachs Group reduced their target price on Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating on the stock in a report on Wednesday, May 27th. Stifel Nicolaus dropped their price target on Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating for the company in a research note on Friday, April 17th. Finally, Bank of America cut their price objective on shares of Abbott Laboratories from $120.00 to $102.00 in a research report on Friday, June 12th. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Abbott Laboratories currently has an average rating of “Moderate Buy” and a consensus target price of $118.61.

Abbott Laboratories Price Performance

ABT stock opened at $103.13 on Friday. The stock has a market cap of $179.63 billion, a price-to-earnings ratio of 33.38, a P/E/G ratio of 2.00 and a beta of 0.61. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.39 and a quick ratio of 1.01. The company has a 50 day simple moving average of $91.61 and a 200 day simple moving average of $101.33. Abbott Laboratories has a 1 year low of $81.97 and a 1 year high of $137.49.

Abbott Laboratories (NYSE:ABT) last issued its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, beating analysts’ consensus estimates of $1.28 by $0.03. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.65%. The firm had revenue of $12.51 billion for the quarter, compared to analyst estimates of $12.52 billion. During the same quarter last year, the business posted $1.26 earnings per share. The company’s quarterly revenue was up 13.0% on a year-over-year basis. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Research analysts anticipate that Abbott Laboratories will post 5.52 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, August 17th. Investors of record on Wednesday, July 15th will be given a dividend of $0.63 per share. The ex-dividend date is Wednesday, July 15th. This represents a $2.52 annualized dividend and a yield of 2.4%. Abbott Laboratories’s dividend payout ratio (DPR) is currently 81.55%.

Insiders Place Their Bets

In other Abbott Laboratories news, Director Daniel J. Starks purchased 10,000 shares of the firm’s stock in a transaction on Monday, April 27th. The stock was purchased at an average cost of $92.65 per share, for a total transaction of $926,500.00. Following the transaction, the director owned 6,751,103 shares in the company, valued at $625,489,692.95. The trade was a 0.15% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 0.46% of the stock is owned by insiders.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.